Clinical trials referenced in this document:
Documents that mention this clinical trial
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
New drugs in preclinical and early stage clinical development in the treatment of heart failure
Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND
Nonglycemic Outcomes of Antidiabetic Medications
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
A novel kidney disease index reflecting both the albumin-to-creatinine ratio and estimated glomerular filtration rate, predicted cardiovascular and kidney outcomes in type 2 diabetes
Funding for this research was provided by:
Eli Lilly and Company
Received: 29 March 2022
Accepted: 14 June 2022
First Online: 22 August 2022
: The protocol was reviewed by Research Ethics Boards for 371 sites in 24 countries and all participants provided signed written informed consent.
: Not applicable.
: HCG holds the McMaster-Sanofi Population Health Institute Chair in Diabetes Research and Care. He reports research grants from Eli Lilly, AstraZeneca, Merck, Novo Nordisk, and Sanofi; honoraria for speaking from Eli Lilly, Novo Nordisk, Sanofi, DKSH, Roche and Zuellig; and consulting fees from Abbott, Covance, Eli Lilly, Novo Nordisk, Sanofi, Pfizer, Kowa and Hanmi. AA reports honoraria for speaking from Eli Lilly, Novo Nordisk, and Boehringer Ingelheim; JB reports research grants from Recor and Ablative Solutions; consulting fees from Eli Lilly, Recor, and Up-to-Date. IC reports honoraria for speaking from Medtronic, Eli Lilly, Novo Nordisk, Sanofi Aventis, Astra Zeneca, Boehringer Ingelheim, and Merck Sharp and Dohme; and consulting fees from Medtronic, Eli Lilly, Novo Nordisk and Sanofi Aventis. WCC reports research grants from Eli Lilly, ReCor, and George Medicines. ML owns Eli-Lilly Stock. LAL has received research funding from AstraZeneca, Bayer, Lexicon, and Sanofi; honoraria for speaking from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, and Servier, and has acted as an adviser to AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, Pfizer, and Sanofi. JES reports a research grant from Astra Zeneca and honoraria for speaking and advisory boards from Astra Zeneca, Sanofi, Eli Lilly, MSD, Mylan, Pfizer, Roche, Abbott and Zuellig. PJR has received speaker honoraria from Aspen and Sanofi. WHHS reported as Advisor and/or Speaker for AstraZeneca, Bayer HealthCare, Boehringer Ingelheim Pharmaceuticals., Daiichi-Sankyo, Eli Lilly and Company, Merck Sharp & Dohme, Mitsubishi Tanabe Pharma Corporation, Novartis Pharmaceuticals, Novo Nordisk, Pfizer, Sanofi-Aventis, and Takeda Pharmaceutical Company.TT-K reports consulting fees from Bayer, AstraZeneca, and Hamilton Health Sciences. IT is employed by Eli Lilly and Company and owns Eli Lilly stock. DX reports grants from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Coca Cola India, the Indian Council of Medical Research, Pfizer, United Kingdom Medical Research Council, and Wellcome Trust, and honoraria from Eli Lilly and Sanofi. GRD, FL, NP, JP have nothing to declare.